1. BusinessWire.com: Epicgenetics new collaboration with the University of Illinois From the article: "EpicGenetics is now moving forward in completing necessary safety testing of these immune system modulating methods with the expectation that human trials will follow soon thereafter. The

1. HealthRising.org: Did an immune hole in the gut open the door for ME/CFS (and long COVID)? From the article: "The gut problems preceded the exposure to the Epstein-Barr virus; that is, the people who later developed a more severe form of ME/CFS – the kind that most of the people reading

1. BioSpace.com: Tonix Pharmaceuticals Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia I have to give Tonix Pharmaceuticals and its CEO Seth Lederman credit: They will not give up on bringing TNX-102, a

1. NPR.org: Pain patients and doctors worry the CDC's new opioid guidelines may be damaging (Audio, 4 minutes) From the summary: "Patients with chronic pain and doctors have long raised concerns about the CDC's opioid prescribing guidelines. The agency has drafted a new version, but some worry

1. Tonix Pharmaceuticals: Tonix Pharmaceuticals announces phase 3 RALLY study results for TNX-102 SL 5.6 mg for the management of fibromyalgia From the article: "Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, today announced that, as expected based on

1. Bloomberg Law: Anti-seizure drug targeted for controlled substance restrictions From the article: "The popular pain and seizure drug gabapentin is under fire for its alleged role in America’s overdose crisis, with an influential consumer advocacy group urging the government to classify the

1. Pain News Network: Strict low-calorie diet reduces fibromyalgia symptoms From the article: "After just three weeks on the restricted diet, nearly three out of four participants (72%) experienced symptom reductions of 30% or more, regardless of the amount of weight lost. Patients who showed

1. BioSpace.com: Aptinyx completes enrollment in phase 2b study of NYX-2925 in fibromyalgia From the article: "Based on the results of our previous fibromyalgia study, in which NYX-2925 alleviated patients' symptoms and improved biomarkers of centralized pain processing, we believe it has the